Introduction

Thyroid nodules are frequently detected although their prevalence depends on the studied population and the methods used to detect them. It is estimated that 2–6% of thyroid nodules are detected by palpation whereas 19–35% are detected by ultrasound assessment. However, autopsy data indicate that the prevalence of thyroid lesions can reach even 85% (1-3). The frequency of nodule detection increases with age, particularly after 60 years of age. Of note, only about 5% of nodular lesions in the thyroid are malignant (4,5). Papillary thyroid cancer (PTC) is the most frequently detected malignancy (14.3/100,000 annually in the US) (6). In the recent 4 decades there has been a steady increase in the prevalence of PTC (5,7,8). Routine assessment of suspicious thyroid lesions is based on ultrasound and cytological examination using a fine-needle aspiration biopsy (FNAB). The most prestigious
thyroid associations such as the American Association of Clinical Endocrinologists (AACE), the American Thyroid Association (ATA) and the European Thyroid Association (ETA) provide detailed guidelines on which nodules should be biopsied (9-11). The result of the cytological examination of the cells collected by FNAB is considered to be the most reliable in planning further clinical assessment. When malignancy is suspected, surgery is recommended, whereas in the case of benign lesions, watchful waiting strategy should be adopted.

In 2009, the National Cancer Institute in Bethesda, MD, USA proposed a classification of cells in thyroid cytology and in 2017 the criteria were revised (12). Currently, it is the basic system for reporting thyroid cytopathology that is the basis for further clinical management (Table 1). The system is known as “Bethesda” and is based on six categories, i.e., (I) nondiagnostic/inadequate, (II) benign, (III) atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), (IV) follicular neoplasm or suspicious for a follicular neoplasm, (V) suspicious for malignancy, and (VI) malignant (12).

Although FNAB is a standard and well-recognized diagnostic procedure for suspicious thyroid nodules, it has certain limitations. The procedure is not easy and requires experience. Additionally, the assessment of individual cells can be difficult to interpret and poses a challenge to pathologists. It is estimated that approximately 20–30% of all thyroid nodule biopsies are classified as “indeterminate” and are then mainly assessed as Bethesda class III (13), in which the risk of thyroid cancer is 6–30% (12) and even 48% (14) and Bethesda class IV, which mainly refers to the suspicion of follicular neoplasm. Among thyroid tumors cytologically assessed as “indeterminate” that are surgically resected approximately 15–30% are malignant lesions that require surgical intervention. As a result, the majority of resected nodules are benign and do not require such a radical approach. This has a multidimensional meaning due to the fact that unnecessary surgery is related to constant hormonal treatment and an endocrine follow-up of patients throughout life. Postoperative complications may also occur, which is associated with the psychological burden of patients and a decreased quality of life. Another important issue is connected with the economic aspect of surgery and postoperative care. This means that additional diagnostic markers are needed for the above two groups of the Bethesda system classification. As a result, other independent factors could add to the cytological picture. Sensitivity to detect these lesions is also of crucial importance. Such lesions require surgical treatment due to high potential of malignancy and aggressiveness.

In the current stage of development of genetic techniques, molecular markers seem to be readily available and perfectly adopted for routine use in everyday clinical practice. Significant progress in understanding the molecular biology of thyroid cancer and particularly PTC has encouraged many scientists to develop molecular classifiers that allow them to differentiate between malignant and benign lesions. The results of the Cancer Genome Atlas Network systematized knowledge of molecular events in PTC (15) and showed that most malignant lesions are characterized by changes in the DNA. Currently, patients with cytologically indeterminate thyroid nodules (Bethesda system) usually undergo diagnostic surgery (mainly lobectomy). Therefore, the possible benefit of using a molecular classifier in cytological diagnoses of indeterminate nodules was considered in the 2nd edition

<table>
<thead>
<tr>
<th>Category of the Bethesda system</th>
<th>Meaning</th>
<th>Usual management</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Non-diagnostic or inadequate</td>
<td>Repeat FNA with ultrasound guidance</td>
</tr>
<tr>
<td>II</td>
<td>Benign</td>
<td>Clinical follow-up</td>
</tr>
<tr>
<td>III</td>
<td>AUS/FLUS</td>
<td>Repeat FNA, molecular testing, lobectomy (diagnostic surgery)</td>
</tr>
<tr>
<td>IV</td>
<td>Follicular neoplasm or suspicious for a follicular neoplasm</td>
<td>Molecular testing, lobectomy (diagnostic surgery)</td>
</tr>
<tr>
<td>V</td>
<td>Suspicious for malignancy</td>
<td>Lobectomy or near-total thyroidectomy</td>
</tr>
<tr>
<td>VI</td>
<td>Malignant</td>
<td>Lobectomy or near-total thyroidectomy</td>
</tr>
</tbody>
</table>

Table 1 TBSRTC and usual management after diagnosis

TBSRTC, The Bethesda System for Reporting Thyroid Cytopathology; FNA, fine-needle aspiration; AUS/FLUS, atypia of undetermined significance/follicular lesion of undetermined significance.
of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) and in the ATA guidelines (9,12). According to these recommendations, the use of molecular tests is useful to assess the risk of malignancy so that unnecessary diagnostic surgery could be avoided.

Additionally, the introduction of a new diagnosis by the WHO in 2017 is an important aspect in the diagnosis of thyroid cancer. Classification of Tumors of Endocrine Organs reclassified thyroid tumors and classified tumors of endocrine organs by introducing a new section termed “other encapsulated follicular-patterned thyroid tumors” (16). This section includes diagnoses termed uncertain malignant potentials, which include follicular tumor of uncertain malignant potential, well-differentiated tumor of uncertain malignant potential and a new diagnosis, i.e., non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) that is considered a benign lesion more similar to follicular adenoma in the clinical course of the disease (17).

NIFTP arouses great interest in relation to preoperative diagnosis. To exclude the malignancy of this tumor, it is necessary to rule out any features of invasion that cannot be assessed in biopsy material. Therefore, despite the fact that the use of FNAB of thyroid nodules has reduced unnecessary surgical treatment, it is still not a sufficient method and requires other supportive methods.

**Preoperative diagnosis of thyroid cancer—from a single gene to a molecular classifier**

The use of immunohistochemical (IHC) markers that assess the malignancy of lesions was the first stage of searching for markers that would increase the sensitivity of FNAB. The use of the following markers was postulated: galectin-3, HBME, fibronectin 1 or cytokeratin 19. However, they proved to be insufficient for the assessment of biopsy material (18-21). It was mainly due to the fact that the use of different antibodies and different visualization methods results in difficulties in the interpretation of the IHC. Additionally, the expression of these markers may be also detected in follicular adenomas (22,23).

The increasing knowledge on molecular changes at the DNA level in thyroid cancer cells is a promising field in the search for molecular markers. Of note, knowledge related to the molecular basis of thyroid cancer was mainly related to postoperative material. Only in the last decade has there been an increase in studies using biopsy material. These studies are connected with the analysis of changes in the DNA sequence (DNA mutations) and gene expressions (mRNA analysis).

Due to the fact that PTC is the most prevalent thyroid cancer, it is also best known in terms of molecular characteristics. The first attempts to use the selection of malignant lesions based on cytology were made using single molecular markers most commonly observed in PTC such as BRAF gene mutations, RET and NTRK rearrangements (24-30) or PAX8/PPARγ fusion characteristic of follicular tumors. However, these alterations do not always occur in malignant tumors and the absence of BRAF mutation does not mean that the lesion has no malignant potential. BRAF mutation can be an important marker determining tumor malignancy but mainly in the countries where the prevalence of this mutation is high and reaches even 83% (25). However, the prevalence of BRAF mutation in European countries ranges from 50% to 70% (31,32). In addition, due to the potential tumor heterogeneity, it can occur in single cell clones and may not be detected when low-sensitivity methods are used.

For this reason, multi-gene panels were tested. As a result, the first tumor-specific mutations test was developed from seven genes most characteristic of PTC and follicular thyroid cancer, i.e., point mutations within BRAF, KRAS, HRAS and NRAS genes, and RET/PTC1, RET/PTC3 and PAX8/PPARγ rearrangements (33). After discovering an important role of the NTRK genes family fusion, these molecular markers were also included in the classifier (34). The analytical sensitivity of the molecular test ranged from 38% to 85.6% and the specificity ranged from 95% to 100%. RAS genes mutations and PPRG/P4X8 rearrangement show the lowest sensitivity since they occur in benign and malignant lesions with a variable frequency. Of note, the first tests were performed using molecular techniques of limited sensitivity. However, it was the introduction of highly sensitive and highly effective methods such as oligonucleotide microarrays and next generation sequencing (NGS) that allowed the detection of mutations or gene expressions that were present even in small amounts.

The first gene panel for preoperative diagnostic use, defined as a molecular classifier, was presented in 2010 (35). The classifier was based on the assessment of the expression of 147 genes selected in the study using high density oligonucleotide microarrays. This study was extended by a multicenter prospective study, which involved over 3,900 patients (36).

It was the turning point for preoperative molecular
diagnosis of thyroid tumors. The first NGS test based on the assessment of changes in the DNA sequence for 15 genes was presented in 2013 (37). NGS method allows the assessment of many gene alterations in one analysis. Next, miRNA-based classifier was developed (38). In fact, all the above classifiers form two groups of tests although all of them have the same aim, which is to distinguish between malignant and benign lesions in biopsy material. Some of these classifiers are used to exclude malignant lesions (“rule-out” test), while the others are used to confirm malignant lesions (“rule-in” test). Both types of tests are determined by two values, i.e., negative predictive value (NPV) and positive predictive value (PPV). However, the NPV value allows to assess the probability of benign lesions when the result is negative (the higher the NPV, the higher the probability of a benign lesion). PPV, on the other hand, allows to assess the probability of malignant lesions when the result is positive (the higher the PPV, the higher the probability of a malignant lesion) in a given population. The use of the “rule-in” and “rule-out” molecular tests is given in Figure 1.

Commercially available molecular tests used in preoperative diagnosis of thyroid cancer—are they useful to endocrinologists and surgeons in Europe?

Until recently, there were 4 companies on the US market that offered commercial tests for preoperative diagnosis of thyroid nodules (Veracyte Inc., CBLPath Inc., Interpace Diagnostics Inc. and Rosetta Genomics Inc.). The test developed by Rosetta Genomics Inc., after its bankruptcy, was taken over by Interpace Diagnostics Inc. (Table 2).

The first commercial molecular test for preoperative diagnosis of thyroid nodules was the Afirma gene expression classifier (GEC) test or its new version known as genomic sequencing classifier (GSC; Veracyte Inc., South San Francisco, CA, USA). This is a “rule-out” test which provides the information whether the lesion is benign or suspicious. The first version of this test (GEC) is based on the assessment of mRNA expression using high density oligonucleotide microarrays and was developed on the basis of a 2010 study by Chudova et al. (35). The test is divided into several steps.

The first step includes the assessment of the expression of 25 genes typical of metastases of other cancers to the thyroid gland (breast cancer, kidney carcinoma and melanoma) and Hürthle cell and medullary thyroid cancer (MTC). If the result is defined as “suspicious” or “MTC”, the analysis is terminated and suggests metastasis to the thyroid or MTC. On the other hand, if the result is negative, the appropriate stage of the analysis is introduced, i.e., the assessment of the expression of 142 genes. At this stage, the result is either “benign” or “suspicious”. When the lesion is suspicious, additional assessment of BRAF gene mutation and RET/PTC1 and RET/PTC3 rearrangements is performed. Of note, the aim of the test is to confirm benign lesions (NPV of 94%, sensitivity of 90%; PPV is low and is of 37%). The test has also some disadvantages as malignant lesions derived from Hürthle cells cannot be assessed using this test. In 2018, the latest version of the GSC was introduced (39). It is based on the NGS technique. Both
gene expression and mutations are assessed. The test was
developed to analyze several thousand genes to better detect
lesions derived from Hürthle cells. The estimated cost was
$6,400 in 2018 (40). It should be borne in mind that the
Afirma test is most often validated by independent studies.
Therefore, it is considered the most reliable, commercially
available test (40-42). Many studies showed that the
number of cases that required lobectomy was reduced by
approximately 50% in the AUS/FLUS diagnoses.
ThyroSeq 2 (CBLPath Inc., Rye Brook, New York,
University of Pittsburgh Medical Center, Pittsburgh, PA,
USA) is the second most frequent test used in the cytological
assessment. This test assesses point mutations, small
insertions and deletions for 14 genes, and evaluates 42 fusion
genes. The mutations used in the test are related to the
biology of PTC in as much as 90% (43). The test is intended
to detect malignant lesions (“rule-in”) and the obtained result
may be positive or negative. The positive result indicates that
the lesion has a malignant potential. Interestingly, this test
has high PPV (83%) and also NPV (96%) (sensitivity 90%;
specificity 93%). However, it was not so widely validated by
other independent studies and those which used it showed
significantly lower PPV and NPV values (44,45). The current
version of ThyroSeq3 is characterized by sensitivity of 94%
and specificity of 82% and NPV of 97%, PPV of 66% for
the cancer prevalence of 28% (46) (Steward, 2018). The cost
of the test is USD 4,056 (41).
ThyGenX/ThyraMIR test (Interpace Diagnostics
Inc., Parsippany, NJ, USA) has the similar characteristics.
It is based on the assessment of the mutations of 5 genes,
i.e., \(BRAF, KRAS, HRAS, NRAS, PIK3CA\) and 3 gene
rearrangements, i.e., \(RET/PTC1, RET/PTC3\) and \(P4X8/PPARG\). It is also a “rule-in” test and is characterized
by high NPV (94%) and PPV (74%) (sensitivity 89%;
specificity 85%, respectively) (38). As in the case of the
ThyroSeq test, the result is either positive or negative.
However, to obtain high sensitivity and specificity, it should
be used in combination with second part of the test based on
the assessment of miRNA expression (ThyraMIR). Of note,
each step can be performed separately. However, sensitivity
and specificity are then decreased. The final result of the
two-step assessment shows high or low probability of
malignancy. There are no independent validation tests for
both assays. The cost of the test is USD 5,675 (41).
RosettaGX Reveal (Rosetta Genomics Inc., Philadelphia,
Pennsylvania, USA, currently Interpace Diagnostics
Group, Parsippany, NJ, USA) is another test based on
miRNA expression. It is the only test which also includes
the European cohort. However, it is not well known and
has not undergone multicentre validation. It was found
have sensitivity of 85%, specificity of 72%, NPV of
91%, and PPV of 59% (47). Of note, 3 pathologists were
involved in the cytological assessment, including 1 referring
pathologist. The estimated cost of the test was USD 3,700
in 2018 (40).
Recently, it has been announced that simple and low-
cost classifiers have been developed. Those molecular
tests are based on real-time polymerase chain reaction
(PCR) method which supports FNAB. The tests assess
mRNA or microRNA expression. However, they are still
under research and cannot be commercially used (48,49).
Interestingly, both tests are based on South American
population (Chile and Brazil).
All commercial tests are widely available in the United
States. However, the most significant scientific associations
are not completely ready to include them in their
recommendations. The ATA clinical practice guidelines
recommend a molecular test for diagnosis of indeterminate

<table>
<thead>
<tr>
<th>Molecular test</th>
<th>Methodology</th>
<th>Type of test</th>
<th>Report</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Patel KN, 2018</td>
</tr>
<tr>
<td>ThyroSeq2/3</td>
<td>Gene mutation analysis (DNA)</td>
<td>Rule-in/rule-out</td>
<td>Negative/positive</td>
<td>Nikiforov YE, 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Steward DL, 2018</td>
</tr>
<tr>
<td>ThyGenX/ThyraMIR</td>
<td>Gene mutation analysis (DNA) and miRNA expression analysis (miRNA)</td>
<td>Rule-in/rule-out when both steps are performed</td>
<td>Negative/positive</td>
<td>Labourier E, 2015</td>
</tr>
</tbody>
</table>

GEC, gene expression classifier; GSC, genomic sequencing classifier.
cytology (AUS/FLUS) after consultation with a patient who should be informed about the benefit-risk ratio (9). However, the AACE guidelines which also focus on the use of molecular tests in cytologically indeterminate thyroid nodules are limited to recommendations on performing the assessment of \textit{BRAF} and \textit{RAS} genes mutations and \textit{RET/PTC} and \textit{PAX8/PPRG} rearrangements (10). However, in the case of multigene classifiers, these associations neither recommend nor prohibit them, which is related to the lack of data on a long follow-up period. On the other hand, a 2015 survey by ATA revealed that more than 50% of American clinicians used a molecular test in their daily clinical practice (50). Clinicians (endocrinologists and surgeons) choose the test themselves due to the fact that there are no clear recommendations on the use of molecular tests that support the cytological diagnosis. In the United States or high-income European countries, the costs of the tests are covered by insurance companies. However, the situation is different if the test is to be used in low-income countries where costs related to diagnostic procedures and treatment are largely covered by public health protection systems. Therefore, the most important disadvantage of commercially available tests is probably related to their price that reaches several thousand dollars. Of note, in many European countries this amount of money is equal to the cost of thyroidectomy. Additionally, there are also other limitations such as the lack of large-scale validation tests involving the European population or a too short follow-up. These limitations are stressed by European experts and therefore they are not included in European recommendations on the diagnosis of thyroid nodules (11).

No analyses of currently available molecular classifiers (commercial or scientific) have been conducted in Europe yet. Of note, there is no molecular test whose price would be affordable for all European patients or European health care systems. Admittedly, the first results of using a cost-effective (EUR 150/sample) molecular classifier in the European population was presented during the ETA Conference in 2019. However, only 109 FNABs were tested (51). The test is based on a custom Mass Array platform (PTC-MA), which allows the simultaneous detection of 13 hotspot mutations and 7 fusion genes characteristic of thyroid cancer (52).

Conclusions

Cytologically indeterminate thyroid nodules pose a great challenge to pathologists, clinicians and molecular biologists. The use of single molecular markers for thyroid cancer might help to detect malignancy in FNAB (e.g., \textit{BRAF} gene mutation). However, this solution is still not sufficient. The use of commercially available molecular tests significantly reduces the number of patients in whom diagnostic surgical intervention is necessary. However, validation and prospective studies are still necessary to assess the tests in other than the North American population. Additionally, the high cost of tests limits their availability in low-income countries.

Acknowledgments

We wish to thank Assistant Professor Arkadiusz Badziński DHSc for assistance in the translation of the manuscript.

Funding: This work was supported by the National Centre for Research and Development project under the program “Prevention practices and treatment of civilization diseases” STRATEGMED (STRATEGMED2/267398 /4/NCBR/2015).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

7. Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 2014;99:E276-85.


30. Chung KW, Yang SK, Lee GK, et al. Detection of
BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006;65:660-6.